Venous Thromboembolism Vte clinical trials

Explore recruiting venous thromboembolism vte clinical trials.

Recruiting venous thromboembolism vte studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Venous Thromboembolism Vte trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3, Multicenter, Randomized, Open-Label, Study to Evaluate REGN7508, A Factor XI Monoclonal Antibody, Versus Apixaban and Enoxaparin for Prophylaxis of Venous Thromboembolism After Elective Total Knee Arthroplasty (ROXI-APEX).

Bulgaria, Lithuania, Poland, Hungary, Latvia, Romania

Therapeutic confirmatory (Phase III) EU CTIS Study details

A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE (ASTER)

Latvia, Ireland, Italy, Czechia, Spain, Germany +6 more

Phase II and Phase III (Integrated) EU CTIS Study details

Is there an effect of local vaginal estrogen treatment on the hemostatic parameters in postmenopausal women?

Denmark

Therapeutic use (Phase IV) EU CTIS Study details

A Phase 3, Multicenter, Double-Blinded, Randomized Study to Evaluate REGN7508, a Factor XI Monoclonal Antibody, Versus Acetylsalicylic Acid for Prophylaxis of Symptomatic Venous Thromboembolism After Elective Total Knee Arthroplasty (ROXI-ASPEN)

Greece, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

Avoiding Risks of Thrombosis and bleeding in Surgery (ARTS): an international randomised controlled trial evaluating apixaban versus no anticoagulation in patients undergoing general abdominal, gynecologic and urologic surgery

Finland

Therapeutic use (Phase IV) EU CTIS Study details

A Phase 2, Multicenter, Randomized, Open-Label, Active-Control Study of REGN9933, a Factor XI Monoclonal Antibody, for Prevention of Venous Thromboembolism after Elective, Unilateral, Total Knee Arthroplasty

Lithuania, Latvia, Poland, Hungary, Bulgaria, Belgium

Therapeutic exploratory (Phase II) EU CTIS Study details

Venous Thromboembolism Vte trials by city

Venous Thromboembolism Vte in Toronto Venous Thromboembolism Vte in Vancouver Venous Thromboembolism Vte in Montreal Venous Thromboembolism Vte in Calgary Venous Thromboembolism Vte in Edmonton Venous Thromboembolism Vte in Ottawa Venous Thromboembolism Vte in Winnipeg Venous Thromboembolism Vte in Quebec City Venous Thromboembolism Vte in Hamilton Venous Thromboembolism Vte in Kitchener Venous Thromboembolism Vte in London Venous Thromboembolism Vte in Halifax Venous Thromboembolism Vte in New York Venous Thromboembolism Vte in Los Angeles Venous Thromboembolism Vte in Chicago Venous Thromboembolism Vte in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease